NBRV.F Stock Overview
A biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nabriva Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.52 |
| 52 Week Low | US$0.000001 |
| Beta | -8.72 |
| 11 Month Change | -99.50% |
| 3 Month Change | n/a |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Nabriva Therapeutics to effect 1-for-25 reverse stock split
Sep 15Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta
Jul 18Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022
Apr 04
Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts
Aug 11We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation
Jul 22Nabriva Therapeutics plc 2021 Q1 - Results - Earnings Call Presentation
May 08When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?
Feb 16Nabriva Therapeutics announces proposed public offering
Dec 10Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China
Dec 07Nabriva Therapeutics plc 2020 Q3 - Results - Earnings Call Presentation
Nov 08Shareholder Returns
| NBRV.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -99.0% | 1.6% | 2.2% |
| 1Y | -100.0% | 10.0% | 31.7% |
Return vs Industry: NBRV.F underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: NBRV.F underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| NBRV.F volatility | |
|---|---|
| NBRV.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NBRV.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NBRV.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 39 | H. Hogan | www.nabriva.com |
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections.
Nabriva Therapeutics plc Fundamentals Summary
| NBRV.F fundamental statistics | |
|---|---|
| Market cap | US$3.00 |
| Earnings (TTM) | -US$55.05m |
| Revenue (TTM) | US$29.56m |
0.0x
P/S Ratio0.0x
P/E RatioIs NBRV.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBRV.F income statement (TTM) | |
|---|---|
| Revenue | US$29.56m |
| Cost of Revenue | US$47.66m |
| Gross Profit | -US$18.11m |
| Other Expenses | US$36.95m |
| Earnings | -US$55.05m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.04 |
| Gross Margin | -61.26% |
| Net Profit Margin | -186.26% |
| Debt/Equity Ratio | -3.3% |
How did NBRV.F perform over the long term?
See historical performance and comparison